Market Overview

UPDATE: Pareto Securities Downgrades AstraZeneca to Sell

Related AZN
AstraZeneca Shares Are Looking Very Weak Right Now
BMO's Bearish Stance On Eli Lilly Comes To An End
3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close (Seeking Alpha)

Pareto Securities reduced its rating on AstraZeneca (NYSE: AZN) from Hold to Sell and lowered its price target from $48 to $44.

Pareto Securities noted, "AstraZeneca (AZN) did not surprise on revenues although margins overall were stronger than consensus expectations. The appointment of a new CEO and recent deals have lifted the valuation to new highs. We do not believe this is sustainable in the short term as 2013E numbers are not strong enough."

AstraZeneca closed at $46.70 on Thursday.

Latest Ratings for AZN

Mar 2018JefferiesUpgradesHoldBuy
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform
Dec 2017JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: Pareto SecuritiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!